Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
  • Jun 07, 2022
サブ-ナビゲーション
  • Company
  • Science/Pipleline
  • 現在位置:News
  • Investor Relations
  • Career
  • Contact
  • Privacy Policy
  • Term of use
  • Sitemap

Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting

  • Jun 07, 2022

VIEW ALL

ページの先頭へ
ページの先頭へ
  • footer-content
  • menu
  • gnavi-box